Study of JZP926 for juvenile myoclonic epilepsy
Part of Brain & nervous system clinical trials.
This study tests an investigational drug called JZP926 (a type of cannabinoid) to see if it can reduce the number of days with myoclonic seizures in people with juvenile myoclonic epilepsy. If you have this condition and are at least 10 years old, you might be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 10 years or older.
- You have been diagnosed with juvenile myoclonic epilepsy (JME).
- You have at least 4 days with myoclonic seizures every 28 days.
- You are not currently taking or using cannabis or CBD products (like Epidiolex).
- You do not have other types of seizures (except generalized tonic-clonic, myoclonic, or absence).
- You are willing to avoid cannabis or CBD products for the duration of the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at EEG brain recordings in people with juvenile myoclonic epilepsy, especially those whose seizures started between ages 10 and 25. It may help researchers better understand how this epilepsy works and improve future care.
This study tests an investigational drug called SPN-817 to see if it can reduce focal seizures (seizures that start in one area of the brain) in adults whose seizures are not well controlled by current medications.
This study tests an experimental pill called PRAX-628 for adults whose seizures are not fully controlled by current medications. It aims to see if the drug is safe and effective at reducing seizures.
This study tests a new oral investigational drug in healthy adults to see how safe it is and how the body handles it. It is an early-phase trial that helps determine the right dose and check for side effects.
This trial tests adding zonisamide to the current epilepsy medication for children aged 1 to 14 who still have focal seizures. The goal is to see if the combination works better and is safe.
This study tests a liquid form of the seizure medicine zonisamide in children aged 1 month to 17 years. It aims to see how the medicine works in the body and whether it is safe and well-tolerated for controlling partial-onset seizures.
Hear when a new Juvenile Myoclonic Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.